Skip to main content

Esophageal Cancer Clinical Trials

Review the esophageal cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 142

Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
The Cardiac Radiation Therapy Sparing for Thoracic Cancers, HEARTS Trial
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Status: Active
Location: See ClinicalTrials.gov
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
Status: Active
Location: See ClinicalTrials.gov
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Status: Active
Location: See ClinicalTrials.gov
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating MM-310 in Patients With Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of BND-35 in Participants With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Status: Enrolling by Invitation
Location: 3 locations
Tremelimumab with Durvalumab to Increase Immune Cells in Patients with Resectable or Locally Advanced Unresectable MSI-Stable or pMMR Esophageal, Gastroesophageal Junction and Gastric Adenocarcinoma with ARID1A Mutations
Status: Approved
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Status: Temporarily Closed to Accrual
Location: 417 locations
Vactosertib for the Treatment of Patients who are Undergoing Standard of Care Chemoradiation for Locally Advanced Esophageal Cancer
Status: Temporarily Closed to Accrual
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care
Status: Temporarily Closed to Accrual
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of gFOLFIRINOX in Treating Patients with Locally Advanced Gastroesophageal or Stomach Cancer
Status: Temporarily Closed to Accrual
Location: 2 locations
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Universal Donor Natural Killer Cells in Combination with Aldesleukin and Vactosertib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal, Gastric and Esophageal Cancers and Relapsed or Refractory Hematologic Cancers
Status: Temporarily Closed to Accrual
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Distance-Based Exercise to Preserve Function and Prevent Disability (DEFEND)
Status: Active
Location: 17 locations
A Study on the Effects of Exercise on Side Effects from Treatment for Gastrointestinal Cancer
Status: Active
Location: 8 locations
My Sleep Our Sleep Program to Improve Insomnia in Patients with Stage I-IV Gastrointestinal Cancer and Their Caregivers
Status: Active
Location: 8 locations
Amiodarone for the Prevention of Atrial Fibrillation after Minimally Invasive Esophagectomy in Patients with Esophageal Cancer
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients with Advanced or Metastatic Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Home-Based Exercise Prehabilitation Program for the Improvement of Physical Fitness and Performance in Patients with Locoregional Esophageal Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Dyadic Mobile Application-based Yoga Program for Improving Physical Function and Quality of Life in Patients with Non-small Cell Lung Cancer or Esophageal Cancer Undergoing Thoracic Radiation Therapy and their Family Caregivers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas